Study: 10% of FDA approved drugs since 2018 had pivotal trials that missed primary endpoints
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct Lifecycle